UK Issues Class 3 Recall for Glucophage SR Tablets Due to Contamination Concerns

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced a Class 3 recall for specific batches of Glucophage SR prolonged-release tablets (500mg, 750mg, and 1000mg). Manufactured by Merck, these diabetes medications are being withdrawn due to a risk of contamination that could impact patient safety.

Why Is Glucophage SR Being Recalled?

The recall was issued as a precautionary measure following concerns over contamination, which could potentially alter the effectiveness of the medication. Glucophage SR is commonly prescribed to manage type 2 diabetes by controlling blood sugar levels, and any compromise in its quality could pose significant health risks.

Who Is Affected?

Patients who use Glucophage SR tablets in 500mg, 750mg, and 1000mg strengths should check their packaging for affected batch numbers. Pharmacists and healthcare professionals have been advised to stop dispensing the recalled batches and return them to suppliers.

What Should Patients Do?

• Continue Taking Your Medication: Unless advised otherwise by a healthcare provider, do not stop taking Glucophage SR abruptly, as this could lead to uncontrolled blood sugar levels.
• Consult Your Doctor or Pharmacist: If you have concerns or are unsure whether your batch is affected, seek medical advice promptly.
• Monitor Symptoms: Patients should be vigilant for any unusual side effects and report them to their healthcare provider immediately.

MHRA’s Response and Next Steps

The MHRA is working closely with Merck and healthcare providers to ensure that patients have access to safe alternatives. Pharmacists and medical professionals are advised to facilitate a smooth transition for those affected by the recall.

This recall highlights the importance of stringent quality control in the pharmaceutical industry to maintain public safety. For more information, visit the official MHRA website or contact your healthcare provider.

#GlucophageSR #MedicineRecall #UKHealthcare #DrugSafety #DiabetesCare #Metformin #PharmaceuticalNews #MHRA #HealthAlert